Loading…
Medicaid Generic Drug Price Fairness Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Medicaid Generic Drug Price Fairness Act of 2015 This bill amends title XIX (Medicaid) of the Social Security Act to increase the amount of rebate with respect to each generic drug in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased, except as provided in special application rules, including a special rule for certain noninnovator multiple source drugs.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2016 · fourth_quarter · Taxation/Internal Revenue Code
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity, and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax, and extenders.
Client expense: $3,820,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2016 · third_quarter · Taxation/Internal Revenue Code
Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity, and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax and extenders.
Client expense: $3,410,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Taxation/Internal Revenue Code
Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity, and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax, and extenders.
Client expense: $3,380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Taxation/Internal Revenue Code
Legislation related to the moratorium on Internet access taxes. Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation and extenders.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Taxation/Internal Revenue Code
Legislation related to the moratorium on Internet access taxes. Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity, and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax, and extenders.
Client expense: $3,720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Budget/Appropriations
Issues related to implementation of the Generic Drug User Fee Agreement (GDUFA), FDA funding Medicaid Generic Drug Rebate, HR. 1314 - Bipartisan Budget Act of 2015, S. 1364- Medicaid Generic Drug Price Fairness Act of 2015
Client expense: $610,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
2015 · fourth_quarter · Taxation/Internal Revenue Code
Legislation related to the moratorium on Internet access taxes. Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, implicity and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax and extenders.
Client expense: $3,940,000 · Firm income: Not reported
2015 · fourth_quarter · Medicare/Medicaid
Medicare Part D Program and Generic Drugs,H.R. 2391 Medicaid Generic Drug Price Fairness Act, S. 1364 Medicaid Generic Drug Price Fairness Act, Medicare reimbursement for biosimilars, The Bipartisan Budget Act of 2015, Fiscal Year 2016 Omnibus Appropriations Act, Covered Outpatient Drugs (CMS-2345-F)
Client expense: $940,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · third_quarter · Medicare/Medicaid
Medicare Part D Program and Generic Drugs,H.R. 2391 Medicaid Generic Drug Price Fairness Act, S. 1364 Medicaid Generic Drug Price Fairness Act, Medicare reimbursement for biosimilars
Client expense: $870,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · third_quarter · Taxation/Internal Revenue Code
Legislation related to the moratorium on Internet access taxes. Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. H.R. 684 and S.336, To restore States' sovereign rights to enforce State and local sales and use tax laws, and for other purposes. S. 1364, A bill to promote neutrality, simplicity, and fairness in the taxation of digital goods and digital services. Implementation of IRC section 181, regarding treatment of film and television productions. Bonus depreciation, alternative minimum tax, and extenders.
Client expense: $3,270,000 · Firm income: Not reported
2015 · second_quarter · Health Issues
Support for KIDS Innovative Drugs Initiative & to include it in the 21st Century Cures proposal. Pediatric Equity Act. Best Pharmaceuticals for Children Act. H.R. 531, Accelerating Biomedical Research Act. H.R. 2104, 21st Century Cures Act. H.R. 2417/S.1364, Foreign Medical School Fairness Act. H.R. 6, 21st Century Cures Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Taxation/Internal Revenue Code
Legislation related to the moratorium on Internet access taxes. Advertising deductibility tax provisions. Reform of the Tax Code, including corporate tax rate. S. 1364, A bill to promote neutrality, simplicity, and fairness in the taxation of digital goods and digital services. Bonus depreciation, alternative minimum tax, and extenders.
Client expense: $3,800,000 · Firm income: Not reported
2015 · second_quarter · Medicare/Medicaid
Medicare Part D Program and Generic Drugs,H.R. 2391 Medicaid Generic Drug Price Fairness Act, S. 1364 Medicaid Generic Drug Price Fairness Act
Client expense: $710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · second_quarter · Medicare/Medicaid
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Health Issues
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Defense
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Labor Issues/Antitrust/Workplace
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Pharmacy
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Postal
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Taxation/Internal Revenue Code
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
| Democratic |
| CT |
| Sheldon Whitehouse | Democratic | RI |
| Sherrod Brown | Democratic | OH |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Copyright Office
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)